Related references
Note: Only part of the references are listed.The MUT056399 Inhibitor of FabI Is a New Antistaphylococcal Compound
S. Escaich et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Challenges of Antibacterial Discovery
Lynn L. Silver
CLINICAL MICROBIOLOGY REVIEWS (2011)
Discovery research: the scientific challenge of finding new antibiotics
David M. Livermore
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Triclosan Resistance of Pseudomonas aeruginosa PAO1 Is Due to FabV, a Triclosan-Resistant Enoyl-Acyl Carrier Protein Reductase
Lei Zhu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
The Kalimantacin/Batumin Biosynthesis Operon Encodes a Self-Resistance lsoform of the Fabl Bacterial Target
Wesley Mattheus et al.
CHEMISTRY & BIOLOGY (2010)
Vinaxanthone, a new FabI inhibitor from Penicillium sp.
Chang Ji Zheng et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Triclosan resistance in clinical isolates of Acinetobacter baumannii
Yagang Chen et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2009)
Inhibitors of Fabl, an enzyme drug target in the bacterial fatty acid biosynthesis pathway
Hao Lu et al.
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase
R. Prisca Massengo-Tiasse et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005
Eili Klein et al.
EMERGING INFECTIOUS DISEASES (2007)
Cephalochromin, a FabI-directed antibacterial of microbial origin
Chang Ji Zheng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Multi-targeting by monotherapeutic antibacterials
Lynn L. Silver
NATURE REVIEWS DRUG DISCOVERY (2007)
Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobactetium tuberculosis
Manzour Hernando Hazbon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Inhibiting bacterial fatty acid synthesis
Yong-Mei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Platensimycin is a selective FabF inhibitor with potent antibiotic properties
J Wang et al.
NATURE (2006)
Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids
CJ Zheng et al.
FEBS LETTERS (2005)
The first sorbicillinoid alkaloids, the antileukemic sorbicillactones A and B, from a sponge-derived Penicillium chrysogenum strain
G Bringmann et al.
TETRAHEDRON (2005)
Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil
RF Cardoso et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase
YM Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Antibacterial resistance worldwide: causes, challenges and responses
SB Levy et al.
NATURE MEDICINE (2004)
Genetic strategies for antibacterial drug discovery
L Miesel et al.
NATURE REVIEWS GENETICS (2003)
Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan:: Kinetic analysis of mutant
S Sivaraman et al.
BIOCHEMISTRY (2003)
Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus
C Slater-Radosti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)